Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Aronson, Ronnie, Grunberger, George, Hanefeld, Markolf, Piatti, PierMarco, Serusclat, Pierre, Cheng, Xi, Zhou, Tianyue, Niemoeller, Elisabeth, Souhami, Elisabeth, Davies, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Errata
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439410/
https://www.ncbi.nlm.nih.gov/pubmed/28420696
http://dx.doi.org/10.2337/dc17-er06c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439410/
https://www.ncbi.nlm.nih.gov/pubmed/28420696
http://dx.doi.org/10.2337/dc17-er06c

Ejemplares similares